CIBC Asset Management
IBRX icon

CIBC Asset Management’s ImmunityBio IBRX Stock Holding History

CIBC Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
+31,794
New +$241K ﹤0.01% 1100
2025
Q1 		– Sell
-20,539
Closed -$52.6K – 1210
2024
Q4 		$52.6K Buy
20,539
+1,102
+6% +$4.59K ﹤0.01% 1204
2024
Q3 		$72.3K Buy
19,437
+733
+4% +$3.39K ﹤0.01% 1187
2024
Q2 		$118K Buy
+18,704
New +$123K ﹤0.01% 1088
2023
Q1 		– Sell
-11,161
Closed -$56.6K – 1098
2022
Q4 		$56.6K Sell
11,161
-4,508
-29% -$24.8K ﹤0.01% 1031
2022
Q3 		$78K Hold
15,669
– – ﹤0.01% 1193
2022
Q2 		$58K Sell
15,669
-1,146
-7% -$4.6K ﹤0.01% 1229
2022
Q1 		$94K Hold
16,815
– – ﹤0.01% 1463
2021
Q4 		$102K Buy
16,815
+1,232
+8% +$9.26K ﹤0.01% 1482
2021
Q3 		$152K Buy
+15,583
New +$171K ﹤0.01% 1401

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC Asset Management's IBRX Position: Q2 2026 in Review

CIBC Asset Management opened a new position in ImmunityBio (IBRX) in Q2 2026: 31,794 shares worth $278K. The stake represents ﹤0.01% of the portfolio and ranks #1100 among its holdings. This is a return to the name: CIBC Asset Management previously reported a position in IBRX as recently as Q4 2024.

CIBC Asset Management first reported a position in IBRX in Q3 2021 and has held it in 10 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • CIBC Asset Management held 31,794 shares of ImmunityBio worth $278K as of Q2 2026.
  • ImmunityBio was a new CIBC Asset Management position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1100 holding.
  • CIBC Asset Management first reported a position in ImmunityBio in Q3 2021 and has held it in 10 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.